# Efavirenz treatment improves retinal vaso-obliteration and pathological neovascularization in a mouse model of retinopathy of prematurity

**Authors:** Briah Bailey, Josephine Rudd Zhong Manis, Gayatri Seth, Shubhra Rajpurohit, Allston Oxenrider, Pamela M. Martin, Ravirajsinh N. Jadeja, Menaka C. Thounaojam

PMC · DOI: 10.3389/fmed.2026.1745351 · Frontiers in Medicine · 2026-02-23

## TL;DR

Efavirenz treatment in mice with a model of retinopathy of prematurity reduces harmful blood vessel growth and improves retinal health.

## Contribution

This study reveals that CYP46A1 activation with efavirenz can alleviate retinal pathologies in a mouse model of retinopathy of prematurity.

## Key findings

- EFV treatment reduced pathological neovascularization and avascular areas in OIR mice retinas.
- EFV limited reactive gliosis and microglia activation while improving retinal ganglion cell survival.
- CYP46A1 and its metabolite 24HC are dysregulated in OIR, and EFV treatment partially reverses this.

## Abstract

Previous studies have shown the metabolic and regulatory significance of CYP46A1 in the adult retina; however, its role in the developing retina is unknown. Here, we evaluate CYP46A1 expression and the impact of its activation in the developing mouse retina under normal and pathological conditions.

Seven-day-old (P7) C57BL/6 J mice maintained in room air (controls) or subjected to oxygen-induced retinopathy (OIR) were treated with/without 20 mg/kg efavirenz (EFV), a CYP46A1 activator administered intraperitoneally from P7 to P17.

Retinal cross sections and flat mounts were prepared to study retinal vasculature morphology, Müller and microglia activation, and ganglion cell viability. EFV treatment significantly reduced pathological neovascularization and the size of avascular and hypoxic areas in OIR mice retinas. EFV treatment additionally limited reactive gliosis and microglia activation and improved retinal ganglion cell survival in OIR mice.

The current study demonstrates the developmental regulation of CYP46A1 and the dysregulated expression and levels of the downstream metabolite 24-Hydroxycholesterol (24HC) in OIR mice. The study further suggests that EFV treatment (in part via CYP46A1 activation) may improve key pathological features associated with pathological neovascularization in OIR mice.

## Linked entities

- **Genes:** CYP46A1 (cytochrome P450 family 46 subfamily A member 1) [NCBI Gene 10858]
- **Chemicals:** efavirenz (PubChem CID 3203), 24-Hydroxycholesterol (PubChem CID 121948)
- **Diseases:** retinopathy of prematurity (MONDO:0006952)

## Full-text entities

- **Genes:** Cyp46a1 (cytochrome P450, family 46, subfamily a, polypeptide 1) [NCBI Gene 13116] {aka CH24H, Cyp46}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, Vcam1 (vascular cell adhesion molecule 1) [NCBI Gene 22329] {aka CD106, Vcam-1}, ALOX15 (arachidonate 15-lipoxygenase) [NCBI Gene 246] {aka 12-LOX, 15-LOX, 15-LOX-1, LOG15}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, CYP2C8 (cytochrome P450 family 2 subfamily C member 8) [NCBI Gene 1558] {aka CPC8, CYP2C8DM, CYPIIC8, MP-12/MP-20}, Cyp27a1 (cytochrome P450, family 27, subfamily a, polypeptide 1) [NCBI Gene 104086] {aka 1300013A03Rik, Cyp27}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, ACAT1 (acetyl-CoA acetyltransferase 1) [NCBI Gene 38] {aka ACAT, MAT, T2, THIL}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, CYP46A1 (cytochrome P450 family 46 subfamily A member 1) [NCBI Gene 10858] {aka CP46, CYP46}, PPIG (peptidylprolyl isomerase G) [NCBI Gene 9360] {aka CARS-Cyp, CYP, SCAF10, SRCyp}, CYP27A1 (cytochrome P450 family 27 subfamily A member 1) [NCBI Gene 1593] {aka CP27, CTX, CYP27}, CYP4F3 (cytochrome P450 family 4 subfamily F member 3) [NCBI Gene 4051] {aka CPF3, CYP4F, CYPIVF3, LTB4H}, Iba1 (induction of brown adipocytes 1) [NCBI Gene 114737], Icam1 (intercellular adhesion molecule 1) [NCBI Gene 15894] {aka CD54, Icam-1, Ly-47, MALA-2}, CYP1B1 (cytochrome P450 family 1 subfamily B member 1) [NCBI Gene 1545] {aka ASGD6, CP1B, CYPIB1, GLC3A, P4501B1}, RBPMS (RNA binding protein, mRNA processing factor) [NCBI Gene 11030] {aka HERMES}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, Nr1h3 (nuclear receptor subfamily 1, group H, member 3) [NCBI Gene 22259] {aka LXR, RLD1, Unr1}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}
- **Diseases:** retinopathy (MESH:D058437), dementia (MESH:D003704), retinal diseases (MESH:D012164), strabismus (MESH:D013285), neuropsychiatric and hepatic adverse effects (MESH:D056486), glaucoma (MESH:D005901), hypoxic (MESH:D002534), ROP (MESH:D012178), OIR (MESH:D000860), cognitive impairment (MESH:D003072), blindness (MESH:D001766), ocular complication of prematurity (MESH:D005117), hyperoxia (MESH:D018496), amblyopia (MESH:D000550), vision loss (MESH:D014786), gliosis (MESH:D005911), inflammation (MESH:D007249), RNV (MESH:D015861), ischemic (MESH:D002545), retinal inflammation (MESH:D012173), Alzheimer's disease (MESH:D000544)
- **Chemicals:** sterol (MESH:D013261), lipid (MESH:D008055), paraformaldehyde (MESH:C003043), CO2 (MESH:D002245), EFV (MESH:C098320), BA (MESH:D001464), glucose (MESH:D005947), DMSO (MESH:D004121), Cholesterol (MESH:D002784), DAPI (MESH:C007293), SDS (MESH:D012967), PVDF (MESH:C024865), oxysterols (MESH:D000072376), Texas Red (MESH:C034657), PBS (MESH:D007854), Oxygen (MESH:D010100), penicillin (MESH:D010406), 24-Hydroxycholesterol (MESH:C044563), 7alpha-hydroxy-3-oxo-4-cholestenoic acid (MESH:C056891), Bile acids (MESH:D001647), sodium bicarbonate (MESH:D017693), 5-cholestenoic acid (-), streptomycin (MESH:D013307), 27-hydroxycholesterol (MESH:C076996), fatty acid (MESH:D005227), Triton X-100 (MESH:D017830), amino acids (MESH:D000596), F12 (MESH:C007782)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** -3304 — Homo sapiens (Human), Coronary artery disease, Induced pluripotent stem cell (CVCL_JV72), R28 — Rattus norvegicus (Rat), Transformed cell line (CVCL_D502), HMC3 — Homo sapiens (Human), Transformed cell line (CVCL_II76), ATCC  CRL-2302 — Homo sapiens (Human), Hereditary coproporphyria, Transformed cell line (CVCL_W226), ARPE-19 — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0145)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967956/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12967956/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967956/full.md

---
Source: https://tomesphere.com/paper/PMC12967956